YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
(RTTNews) - Heron Therapeutics Inc. (HRTX), a commercial-stage biotechnology company, on Monday released second quarter financial results noting a higher loss due to increased sales expenses and decreased sales of oncology drugs. Heron mar…
Earnings Call Insights: Heron Therapeutics (HRTX) Q2 2026 MANAGEMENT VIEW * “Net revenue for the quarter was $37.7 million… it is below what we expected of ourselves,” said (CEO & Director Craig Collard), adding that “CINVANTI sales were u…
Key Points Interested in Heron Therapeutics, Inc.? Here are five stocks we like better. Second-quarter net revenue rose to $37.7 million, but sales of key products fell short of management's expectations. ZYNRELEF sales increased 35% year…
Major earnings expected before the bell on Monday include: * Barrick Mining Corporation (B [https://seekingalpha.com/symbol/B]) * Medical Properties Trust (MPT [https://seekingalpha.com/symbol/MPT]) * Seadrill Limited (SDRL [https://seekin…
BioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $0.3 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.15 per share a year ago. These figures are adjusted for non-recurr…
Intuitive Surgical (NASDAQ:ISRG) beat both top- and bottom-line consensus estimates in its fiscal Q2 2026 results, with revenue for the quarter growing 19% to $2.89 billion and adjusted EPS reaching $2.80, exceeding expectations by $0.30.…
We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Heron Therapeutics, Inc. (NASDAQ:HRTX) is one of the most promising stocks on our list. TheFly reported on June 3 that H.C. Wainwright lo…
Healthcare stocks declined late Tuesday afternoon, with the NYSE Healthcare Index decreasing 0.8% an PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
We recently compiled a list of the 10 Best Penny Stocks Under $1 According to Hedge Funds. Heron Therapeutics, Inc. (NASDAQ:HRTX) is another of the best penny stocks on this list. TheFly reported on May 11 that HRTX saw its price target re…
Heron Therapeutics, Inc. Q1 2026 Earnings Call Summary - Moby Operational Performance and Strategic Drivers Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's o…
Heron Therapeutics logo Key Points Interested in Heron Therapeutics, Inc.? Here are five stocks we like better. Heron reaffirmed its full-year 2026 outlook despite a weak first quarter, with net product sales of $34.7 million and adjusted…
medical research 10 ©Pixnio Heron Therapeutics maintained its full-year outlook as growth in its Acute Care franchise helped offset ongoing weakness in oncology products during the first quarter. Key Investor Takeaways Heron Therapeutics,…
Major earnings expected before the bell on Monday include: * Barrick Mining Corporation (B [https://seekingalpha.com/symbol/B]) * Circle Internet Group (CRCL [https://seekingalpha.com/symbol/CRCL]) * Cronos Group (CRON [https://seekingalph…
ARS Pharmaceuticals, Inc. (SPRY) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook gives a good sense of the company…
Wall Street expects a year-over-year decline in earnings on lower revenues when Heron Therapeutics (HRTX) reports results for the quarter ended March 2026. While this widely-known consensus outlook is important in gauging the company's ear…
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Heron Therapeutics, Inc. (HRTX) : Free Stock Analysis Report AstraZeneca PLC (AZN) :…
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Heron Therapeutics, Inc. (HRTX) : Free Stock Analysis Report AstraZeneca PLC (AZN) :…
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Humana Inc. (HUM) : Free Stock Analysis Report Heron Therapeutics, Inc. (HRTX) : Free…
Heron Therapeutics, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Execution and Performance Drivers The company successfully completed a financing round that eliminated a long-standing capital structure overhang, allowing management…
Earnings Call Insights: Heron Therapeutics (HRTX) Q4 2025 MANAGEMENT VIEW * CEO Craig Collard emphasized the "successful completion of our financing," describing it as a "meaningful derisking event" that enables the company to focus on "co…
Major earnings expected before the bell on Thursday include: * Viatris (VTRS [https://seekingalpha.com/symbol/VTRS]) * Baidu (BIDU [https://seekingalpha.com/symbol/BIDU]) * Vistance Networks (VISN [https://seekingalpha.com/symbol/VISN]) *…
“We are encouraged by the growth in Q4 2025, driven in particular by the momentum in our Acute Care franchise with ZYNRELEF and APONVIE,” said Craig Collard, CEO. “In addition to our revenue growth, we are extremely pleased with the contin…
[$10 Banknote Stacking, Green Up Arrow Rise] spawns Heron Therapeutics (HRTX [https://seekingalpha.com/symbol/HRTX]) added ~14% on Friday after the company announced its preliminary and unaudited net revenue figures for Q4 and full-year 20…
The following are today's upgrades for Validea's Growth/Value Investor model based on the published strategy of James P. O'Shaughnessy. This two strategy approach offers a large-cap value model and a growth approach that looks for persiste…
APONVIE, an aprepitant product, highlighted as the only FDA-approved IV formulation Neurokinin-1 (“NK-1”) antagonist indicated for the prevention of PONV in adults, with a long half-life and quicker onset than oral aprepitant Aprepitant al…
The following are today's upgrades for Validea's Growth/Value Investor model based on the published strategy of James P. O'Shaughnessy. This two strategy approach offers a large-cap value model and a growth approach that looks for persiste…
CARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced the appointment of Thomas Cusack to its Board of Directors. Mr. Cus…
CARY, N.C., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tu…
* Heron Therapeutics (NASDAQ:HRTX [https://seekingalpha.com/symbol/HRTX]) filed a prospectus for the offer and sale of $125M mixed securities shelf. * This prospectus is not an offer to sell these securities. * Filing. [https://seekingalph…
Rubric Capital Management LP, a ten percent owner of HERON THERAPEUTICS, INC. /DE/ (NASDAQ:HRTX), acquired 2,387,225 shares of common stock at $1.50 per share, for a total transaction value of $3,580,837. The purchase comes as the stock tr…
Earnings Call Insights: Heron Therapeutics (HRTX) Q2 2025 MANAGEMENT VIEW * CEO Craig Alexander Collard highlighted the successful completion of new financing as “one of the most significant milestones this quarter,” stating it “strengthen…
Stay up-to-date with the latest market trends in the middle of the day on Friday. Explore the top gainers and losers during today's session in our detailed report. [topmovers] TOP GAINERS TICKER CHANGE COMMENT SGBX [https://www.chartmill.c…
The session on Friday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. [gap] TOP GAP UP STOCKS TICKER CHANGE COMMENT ORIS [https://www.chartm…
Heron Therapeutics (HRTX) said Friday it has completed its capital restructuring to boost financial PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
* Heron Therapeutics press release [https://seekingalpha.com/pr/20194787-heron-therapeutics-announces-q2-2025-financial-results-and-highlights-commercial-progress] (NASDAQ:HRTX [https://seekingalpha.com/symbol/HRTX]): Q2 GAAP EPS of -$0.02…
CARY, N.C., Aug. 8, 2025 Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the completion of a comprehensive capital restructuring designed to enhance the Company'…